Therefore, inactivating GNAS pathogenic variants from maternal allele leads to a dramatic reduction in Gsα expression, characterized by end-organ resistance to multiple hormones, primarily PTH and TSH, causing hypocalcemia, hyperphosphatemia, elevated PTH levels and hypothyroidism [3]. The gene discussed is PTH; the disease is hyperphosphatemia.